Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch
Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor
Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor
View: Text | PDF
Research Article Cell biology Oncology

Wnt/β-catenin–activated Ewing sarcoma cells promote the angiogenic switch

  • Text
  • PDF
Abstract

Wnt/β-catenin signaling is active in small subpopulations of Ewing sarcoma cells, and these cells display a more metastatic phenotype, in part due to antagonism of EWS-FLI1–dependent transcriptional activity. Importantly, these β-catenin–activated Ewing sarcoma cells also alter secretion of extracellular matrix (ECM) proteins. We thus hypothesized that, in addition to cell-autonomous mechanisms, Wnt/β-catenin–active tumor cells might contribute to disease progression by altering the tumor microenvironment (TME). Analysis of transcriptomic data from primary patient biopsies and from β-catenin–active versus –nonactive tumor cells identified angiogenic switch genes as being highly and reproducibly upregulated in the context of β-catenin activation. In addition, in silico and in vitro analyses, along with chorioallantoic membrane assays, demonstrated that β-catenin–activated Ewing cells secreted factors that promote angiogenesis. In particular, activation of canonical Wnt signaling leads Ewing sarcoma cells to upregulate expression and secretion of proangiogenic ECM proteins, collectively termed the angiomatrix. Significantly, our data show that induction of the angiomatrix by Wnt-responsive tumor cells is indirect and is mediated by TGF-β. Mechanistically, Wnt/β-catenin signaling antagonizes EWS-FLI1–dependent repression of TGF-β receptor type 2, thereby sensitizing tumor cells to TGF-β ligands. Together, these findings suggest that Wnt/β-catenin–active tumor cells can contribute to Ewing sarcoma progression by promoting angiogenesis in the local TME.

Authors

Allegra G. Hawkins, Elisabeth A. Pedersen, Sydney Treichel, Kelsey Temprine, Colin Sperring, Jay A. Read, Brian Magnuson, Rashmi Chugh, Elizabeth R. Lawlor

×

Figure 1

Wnt/β-catenin activation in primary patient biopsies is associated with increased angiogenesis.

Options: View larger image (or click on image) Download as PowerPoint
Wnt/β-catenin activation in primary patient biopsies is associated with ...
(A and B) Gene ontology analysis of LEF1-correlated genes (r > 0.5) was performed for 2 independent patient cohorts: GSE63157 (N = 46 Ewing tumors) and GSE34620 (N = 117 Ewing tumors). The top 5 most enriched biologic processes for each cohort are shown. GSE63157 (N = 46 Ewing tumors): ECM organization, 35 genes; cell adhesion, 46 genes; and angiogenesis, 38 genes. GSE34620 (N = 117 Ewing tumors): ECM organization, 57 genes; cell adhesion, 80 genes; and angiogenesis, 46 genes. For gene ontology (A and B), multiple test comparison was computed using FDR. Only gene sets with FDR < 0.05 are displayed. (C) Pearson’s correlation (r) between LEF1 and endothelial cell markers CDH5 and PECAM1 (with associated 95% CIs) in tumor biopsies. (D) Pearson’s correlation (r) and 95% CI between LEF1 and established target genes of Wnt/β-catenin in endothelial cells (MYC, CCND1). Gene expression data expressed as log2 signal intensity. (E and F) Pearson’s correlations (r) of LEF1 expression (error bars: 95% CIs) with 33 gene prognostic signatures in 2 independent patient cohorts. The first 5 genes were identified as good prognosis biomarkers whereas high expression of the remaining 28 genes (below horizontal dotted line) was associated with poor prognosis. NS, not significant; ND, no data available for indicated gene. Two-sided t tests were used to compute P values for C–F, and P values are shown for each gene. *P < 0.05, **P < 0.005, ***P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts